Agios Pharmaceuticals (AGIO) Other Gross PP&E Adjustments (2016 - 2026)
Agios Pharmaceuticals (AGIO) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with -$27.2 million as the latest value for Q1 2026.
- For Q1 2026, Other Gross PP&E Adjustments rose 31.77% year-over-year to -$27.2 million; the TTM value through Mar 2026 reached -$27.2 million, up 31.77%, while the annual FY2025 figure was $22.1 million, 424.74% up from the prior year.
- Other Gross PP&E Adjustments hit -$27.2 million in Q1 2026 for Agios Pharmaceuticals, down from $22.1 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $22.1 million in Q4 2025 and bottomed at -$62.5 million in Q1 2023.
- Average Other Gross PP&E Adjustments over 5 years is -$28.9 million, with a median of -$35.2 million recorded in 2025.
- Year-over-year, Other Gross PP&E Adjustments tumbled 93440.62% in 2023 and then surged 424.74% in 2025.
- Agios Pharmaceuticals' Other Gross PP&E Adjustments stood at -$18.3 million in 2022, then skyrocketed by 57.66% to -$7.8 million in 2023, then soared by 154.22% to $4.2 million in 2024, then soared by 424.74% to $22.1 million in 2025, then plummeted by 223.31% to -$27.2 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$27.2 million, $22.1 million, and -$33.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.